— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...
TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Application ...
EXPAREL (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via ...
The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...
TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
According to the American College of Surgeons, 15 million Americans undergo surgery each year. Despite this high frequency and the significant impact these procedures can have on patients, no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results